Friday, April, 19, 2019 04:25:34

Zynerba wins U.S. patent for CBD based Fragile X Syndrome treatment

The new patent will be valid until 2038 while the firm expects to present ongoing study reports by the second half of 2019. Zynerba Pharmaceuticals, Inc., the leading developer of innovative pharmaceutically-produced transdermal cannabinoid treatments designed for treating rare and near-rare neuropsychiatric disorders, has recently …